drugset / Trial / NCT01930175

Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris

NCT01930175

Phase 2 Terminated 13 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The study evaluated the efficacy, safety and pharmacokinetics of VAY736 in the treatment of patients with pemphigus vulagaris (PV).

Timeline

Start
2013-12-18
Primary completion
2019-09-25
Completion
2019-09-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Ianalumab Monoclonal antibody 3 mg/kg Intravenous
Subject Ianalumab Monoclonal antibody 10 mg/kg Intravenous

Indications